Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.56 |
| ▸ | GALR3 | O60755 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 3/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29634669 | 1.00 | HTT (0.58) | HTTEGFRKDM4CPOLBNR2F2 | |
| SCHEMBL11827284 | 0.83 | STAT1 (0.62) | HTTKDM4CPOLBGALR3MEN1 | |
| SCHEMBL16781105 | 0.82 | LMNA (0.58) | HTTEGFRPOLBNR2F2MEN1 | |
| SCHEMBL7746233 | 0.82 | CNR1 (0.54) | KDM4CGALR3MAPTALDH1A1RAB9A | |
| SCHEMBL10873653 | 0.81 | KDM4C (0.60) | HTTEGFRKDM4CPOLBGALR3 | |
| SCHEMBL18786736 | 0.81 | HTT (0.56) | HTTEGFRPOLBNR2F2MEN1 | |
| SCHEMBL783719 | 0.81 | KDM4C (0.72) | HTTEGFRKDM4CNR2F2GALR3 | |
| SCHEMBL30983851 | 0.81 | KDM4C (0.72) | HTTEGFRKDM4CNR2F2GALR3 | |
| SCHEMBL20061544 | 0.81 | AURKA (0.59) | HTTEGFRPOLBNR2F2MEN1 | |
| SCHEMBL22307619 | 0.81 | CYP1A2 (0.58) | MEN1KMT2ALMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-1756113-B1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM GMBH (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-8236809-B2 | Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation | VASOPHARM GMBH (DE) | 2012-08-07 | — | — | US | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-7045529-B2 | Imidazopyrimidinyl and imidazopyri dinyl derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| WO-2005111041-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM BIOTECH GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598354-A1 | Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation | Vasopharm Biotech GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20040229887-A1 | Novel imidazopyrimidinyl and imidazopyri dinyl derivatives | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-18 | — | — | US | disclosed |
| EP-1244666-A1 | IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES | Bristol-Myers Squibb Pharma Company (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001044248-A1 | IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-0686631-B1 | Pyrimidine derivatives and pharmaceutical compositions | KUREHA CHEMICAL IND CO LTD (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-5585381-A | HYPOTENSIVE AGENT AND ALSO TREATING KIDNEY RENAL DISEASE | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-12-17 | — | — | US | disclosed |
| EP-0686631-A1 | Pyrimidine derivatives and pharmaceutical composition | Kureha Chemical Industry Co., Ltd. (JP) | 1995-12-13 | — | — | EP | disclosed |
| EP-0206415-A2 | (4-Piperidinylmethyl and -hetero)purines | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229887-A1 | Novel imidazopyrimidinyl and imidazopyri dinyl derivatives | CRH, GPR119, CRHR1 | HTT 99/4885EGFR 4453/4885KDM4C 4789/4885 |
| US-20070203159-A1 | Purine compounds | PNP, UMPS, TYMP | HTT 4116/4885EGFR 4753/4885KDM4C 2955/4885 |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | HTT 2778/4885EGFR 4709/4885KDM4C 797/4885 |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | PRSS8, PRSS1, PRSS2 | HTT 1453/4885EGFR 4135/4885KDM4C 3850/4885 |
| US-10774083-B2 | Heterocyclic amide compound | PRSS8, PRSS1, PRSS2 | HTT 1453/4885EGFR 4135/4885KDM4C 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.